Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Entera Bio Ltd. (ENTX)

0.7092   -0.001 (-0.13%) 11-25 13:00
Open: 0.69 Pre. Close: 0.7101
High: 0.74 Low: 0.69
Volume: 15,199 Market Cap: 20(M)

Technical analysis

as of: 2022-11-25 1:56:43 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.06     One year: 1.24
Support: Support1: 0.63    Support2: 0.47
Resistance: Resistance1: 0.91    Resistance2: 1.06
Pivot: 0.63
Moving Average: MA(5): 0.69     MA(20): 0.66
MA(100): 1.22     MA(250): 1.92
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 64.9     %D(3): 64.3
RSI: RSI(14): 47.7
52-week: High: 3.5  Low: 0.47
Average Vol(K): 3-Month: 130 (K)  10-Days: 307 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ENTX ] has closed below upper band by 20.2%. Bollinger Bands are 38.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.72 - 0.72 0.72 - 0.73
Low: 0.66 - 0.67 0.67 - 0.67
Close: 0.7 - 0.71 0.71 - 0.71

Company Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Headline News

Mon, 21 Nov 2022
New Strong Buy Stocks for November 21st - Nasdaq

Fri, 18 Nov 2022
Ardelyx (ARDX) Up 41% After FDA Committee Endorses CKD Drug - Nasdaq

Thu, 17 Nov 2022
4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why - Nasdaq

Wed, 16 Nov 2022
Should You Sell Entera Bio Ltd (ENTX) Stock Wednesday? - InvestorsObserver

Wed, 16 Nov 2022
Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down - Nasdaq

Wed, 16 Nov 2022
New Strong Buy Stocks for November 16th - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 29 (M)
% Held by Insiders 2.006e+007 (%)
% Held by Institutions 20.3 (%)
Shares Short 26 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.433e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -3
Return on Assets (ttm) 451.3
Return on Equity (ttm) -37.5
Qtrly Rev. Growth 417000
Gross Profit (p.s.) -31.37
Sales Per Share -35.31
EBITDA (p.s.) 104211
Qtrly Earnings Growth -0.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 2.24

Stock Dividends

Dividend 0
Forward Dividend 148080
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.